Induction of Macrolide Resistance Post Azithromycin or Erythromcyin Treatment
Phase 3
Not yet recruiting
- Conditions
- macrolide resistance
- Registration Number
- ACTRN12617000278336
- Lead Sponsor
- Mater misericordiae Ltd, South Brisbane
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie macrolide resistance induction by azithromycin or erythromycin in healthy participants?
How does the intensity of macrolide resistance induction in ACTRN12617000278336 compare to standard-of-care treatments for bacterial infections?
Are there specific biomarkers associated with increased risk of macrolide resistance following azithromycin or erythromycin therapy?
What are the potential adverse events and management strategies for macrolide resistance development in ACTRN1261700027836 participants?
What combination therapies or alternative drug classes could mitigate macrolide resistance induced by azithromycin or erythromycin?